Position in NVS
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$1,960,567
+$34,084 QoQ
Shares Held
12,510
-0.8% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.41%
of 13F equity value
Holder Rank
#436
of 1,603 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026PCM Encore, LLC holds $26,243,532 across 14 Drug Manufacturers - General names. NVS ranks #4 (7.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
8,838 | $10,600,563 | |
| 2 | ABBV |
AbbVie Inc.
|
10,979 | $2,762,755 | |
| 3 | MRK |
Merck & Co., Inc.
|
17,958 | $2,307,603 | |
| 4 | NVS |
Novartis AG
This page
|
12,510 | $1,960,567 | |
| 5 | JNJ |
Johnson & Johnson
|
7,539 | $1,914,679 | |
| 6 | AMGN |
Amgen Inc
|
4,405 | $1,595,138 | |
| 7 | AZN |
Astrazeneca PLC
|
8,087 | $1,533,456 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
7,399 | $934,789 |
All Filings in NVS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,960,567 | 12,510 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $1,926,483 | 12,612 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $1,636,930 | 11,873 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||